Oxaliplatin

Catalog No.S1224 Synonyms: L-OHP

Oxaliplatin Chemical Structure

Molecular Weight(MW): 397.29

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Cleaved caspases and p-H2AX expression were detected by western blot in HCT116 cells (E) and HT29 cells (F). The cells were co-cultured with F. nucleatum or treated with CQ, and different concentrations of Oxaliplatin and 5-FU.

    Cell, 2017, 170(3):548-563.e16. Oxaliplatin purchased from Selleck.

    Intracellular ratio between reduced and oxidized glutathione of the indicated cells treated with oxaliplatin or irinotecan for 6h was measured with spectrophotometric analysis.

    Theranostics, 2018, 8(5): 1312–1326. Oxaliplatin purchased from Selleck.

  • Immunocytochemical staining of SW620 (metastatic) cells after treatment with 10 uM oxaliplatin (F) or 10 uM ginsenosides 20(S)-Rg 3 (G) and negative staining (H). Cells demonstrated differential expression of histone H4.

    J Proteomics 2014 10.1016/j.jprot.2014.10.009. Oxaliplatin purchased from Selleck.

    PDT and oxaliplatin combination treatment. A) Bar graph showing response (total volume of residual viale nodules normalized to no treatment control) to PDT treatmen (2.5 J/cm2), oxaliplatin treatment (10 μM), and PDT followed by oxaliplatin at the same doses. The dramatic enhancement, beyond the additive effect of the two modalities independently suggests there may be a synergistic interaction. B) A representative region from a culture stained with calcein AM and ethidium bromide following treatment with the PDT + oxaliplatin combination shows relatively small pockets of viable disease and many dead relative to untreated cultures.

    Optical Methods for Tumor Treatment and Detection 2013 10.1117/12.2010730. Oxaliplatin purchased from Selleck.

  •  

    Growth inhibitory effects of Oxaliplatin in human pancreatic cancer cells. MiaPaCa-2 cells were plated in triplicates into 48-well plates at a density of 10,000 cells/ml. After 24 hours, complete culture medium was changed into fresh low-serum-containing medium (1% FBS) containing DMSO (control) or indicated doses of Oxaliplatin (Selleckchem). Cell viability 72 hours after treatment was determined by AlamarBlue assay (Invitrogen) according to manufacturer's instructions. Results are expressed as percentages of control, which was arbitrarily assigned 100% viability, and represented as the mean ± standard deviation (SD) of the tripicate wells. 

    2013 Dr. Edita Aksamitiene from Thomas Jefferson University. Oxaliplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 M1fYeWN6fG:2b4jpZ4l1gSCDc4PhfS=> MWmw5qCUOTZywrFOwG0> NEjCfow1QMLiaB?= MUTJR|UxRTVwONMgxtHDqDBwNTFOwG0> MVKyOlQ4PDZ7Mx?=
CaES-17 NGf3b3hEgXSxdH;4bYNqfHliQYPzZZk> NUHwSZhCOOLCk{G2NOKh|ryP M2LZXlQ5yqCq NITsZ5ZKSzVyPUWuOeKhyrIEoECuNkDPxE1? NGq2NY4zPjR5NE[5Ny=>
SW480 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjnOHREPDhiaNMg NIj1Z4RKSzVyPUGuPFch|ryP MkTUNlYzPjl5NUm=
HCT116 Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnzR3A1PDhiaNMg M33ZfmlEPTB;MUGuPFYh|ryP MYKyOlI3QTd3OR?=
LoVo MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHmZ4ZVPDhiaNMg MVTJR|UxRTl2LkizJO69VQ>? NYPoU21EOjZ{Nkm3OVk>
SK-BR-3 NUCwSpVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzoOGRJUUN3ME2zNU4xKMLzIECuNUDPxE1? Mn3MNlYzOTF3OUG=
MCF-7 NHHob45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF3LkSgxtEhOC5|IN88US=> MnzrNlYzOTF3OUG=
MDA-MB-231 NUnVRpdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K0b2lEPTB;MkOuNUDDuSByLkGg{txO NH\KXo8zPjJzMUW5NS=>
HCT116 p53+/+ NW\L[2l5TnWwY4Tpc44hSXO|YYm= M1jERlEwPSEQvF2= NF[2TnIzPC92ODDo M2rn[Ylv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= NEewXFMzPjJyOEWyNy=>
LoVo  NFf4cIFHfW6ldHnvckBCe3OjeR?= NUDuZlVFOS93IN88US=> NXOzcZdCOjRxNEigbC=> NH7uUZBqdmS3Y3XzJJRz[W6|Y4LpdJRqd26jbDDy[ZBz\XO|aX;uJI9nKESXVD3O MoLoNlYzODh3MkO=
SNU-398 M3vGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnCR2dRUUN3ME22MlXDqMLzwrCxMlEh|ryP M1HkOFI3OTZyNEK5
Hep-G2 M3zYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD1bW5vUUN3ME2xN{4yyqEEsdMgNU43KM7:TR?= NEnScGwzPjF4MESyPS=>
SNU-475 M{flSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HEZWlEPTExvK6zNEDPxE1? NIGxO3czPjF4MESyPS=>
SNU-387 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonCTWM2OD1{NdMgxtHDqDJwNzFOwG0> M3\5blI3OTZyNEK5
HT29 NWHrO4lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrmTWM2OD1yLki4xsDDucLiMD6yJO69VQ>? M32zPFI3OTR6NUm2
HCT116 M4DzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTwWoFKSzVyPUCuOFHDqMLzwrCwMlAzKM7:TR?= M4TwelI3OTR6NUm2
PA-1 MVXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{HHe|AuOjBizszN MlHaNlQwPDhiaB?= NWjQTGtxcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NHzEVlkzPjF|OE[3NS=>
OVCAR-5 M3TFb2NmdGxiVnnhZoltcXS7IFHzd4F6 NEPmUm4xNTZyIN88US=> Mn7yNlQwPDhxN{KgbC=> NWnzeXpucW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MnrUNlYyOzh4N{G=
SK-OV-3 MXvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF;ufosxNTFyMDFOwG0> MnnaNlQwPDhxN{KgbC=> NEDXfnhqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MofNNlYyOzh4N{G=
PA-1 MofMSpVv[3Srb36gRZN{[Xl? MoPrNVAh|ryPwrC= M3nqZ|I1cA>? NFzEd2x1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> M4nxS|I3OTN6Nkex
OVCAR-5 MULGeY5kfGmxbjDBd5NigQ>? NYjZRmJzOzBizszN MYW0PIg> MYf0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO= M3HPc|I3OTN6Nkex
SK-OV-3 NEDiR5NHfW6ldHnvckBCe3OjeR?= NVPzTYttPTBizszN MVK5OkBp MWf0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO= M1jZR|I3OTN6Nkex
PA-1 NVnLZY5CTnWwY4Tpc44hSXO|YYm= NHfDS2oyOCEQvF5CpC=> MkPuOFhp NHP4VXd2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? MlHnNlYyOzh4N{G=
OVCAR-5 NYLXTHpSTnWwY4Tpc44hSXO|YYm= MWizNEDPxE1? MYq0PIg> NEPOcZh2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? Mlq2NlYyOzh4N{G=
SK-OV-3 M{X3S2Z2dmO2aX;uJGF{e2G7 M1HKeFUxKM7:TR?= NVLZbW5NQTZiaB?= MXf1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM> MXuyOlE{QDZ5MR?=
PA-1 NWDyNmd[TnWwY4Tpc44hSXO|YYm= Mn31NVAh|ryPwrC= MkXYNlRp MV;wdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= MlPHNlYyOzh4N{G=
OVCAR-5 NVPaZVBWTnWwY4Tpc44hSXO|YYm= MoC1NlAh|ryPwrC= NHy3XVEzPGh? MWHwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= Moj3NlYyOzh4N{G=
SK-OV-3 MlfPSpVv[3Srb36gRZN{[Xl? NEDsfno2OCEQvF5CpC=> NYHyPZJkPDhiaNMg NUHxSnZOeHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM> MV[yOlE{QDZ5MR?=
CT26  M2rlNmZ2dmO2aX;uJGF{e2G7 Mmj5OEBuVQ>? MXy0PEBpyqB? NVz3VmlHcW6mdXPld{BifXSxcHjh[5k> MnXkNlYyOzdyMUK=
CT26  MYPGeY5kfGmxbjDBd5NigQ>? MoTCOEBuVQ>? NFf5e3M1QCCqwrC= NIDUfpRqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wy|IH;mJIF2fG:yaHHnfU1z\WyjdHXkJJBzd3SnaX7zMEB{fWOqIHHzJGxEOy2LSTygRoVkdGmwMTDhcoQhSVSJNR?= MVuyOlE{PzBzMh?=
CT26  NEH6[phE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFW3ZW41KG2P Mo\rOFghcMLi NITrblZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgeI8hPTNwMjW= NYrzSZc2OjZzM{ewNVI>
BE NXzVRY9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nLN2lEPTB;Mz6zN{DPxE1? M3Kwc|I3ODJ|MEi1
Colo205 M37W[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjWUm82UUN3ME2zMlM{KM7:TR?= NYizfY9zOjZyMkOwPFU>
DLD1 M3rlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJwMEGg{txO Mkf2NlYxOjNyOEW=
HT29 NFOyU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vXUmlEPTB;Mj62PUDPxE1? M{TGelI3ODJ|MEi1
HCT15 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jIeWlEPTB;MT60N{DPxE1? M{XlXlI3ODJ|MEi1
HCT116 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj1UINKSzVyPUGuNFQh|ryP M4CyUFI3ODJ|MEi1
HCT116p53- Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLLN25sUUN3ME2xMlA5KM7:TR?= M1PIZlI3ODJ|MEi1
KM12 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jY[2lEPTB;ND6zO{DPxE1? NHPi[HEzPjB{M{C4OS=>
LoVo NFfCVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTTc4ZKSzVyPUGuNkDPxE1? MXKyOlAzOzB6NR?=
RKO MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDoTWM2OD1zLkKzJO69VQ>? MYeyOlAzOzB6NR?=
SW480 NUfvc3BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDBXWxKSzVyPUKuPFYh|ryP NFm1XnMzPjB{M{C4OS=>
SW620 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNwNkig{txO NV3LcldJOjZyMkOwPFU>
MC38 NWT3Tm1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfDTWM2OD1{MzFOwG0hyrFiMh?= NEnkfo8zPjByNEC4OC=>
HT29 M1TvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPUUHdKSzVyPU[zJO69VSEEsTCxPC=> MnH0NlYxODRyOES=
DLD-1 NGS2dY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\OZ2lEPTB;M{KuNkDPxE1? MoPHNlYxODNyOEW=
HT-29 NXr1SFBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;RTWM2OD1|NT62JO69VQ>? NYnw[oF5OjZyMEOwPFU>
SiHa M1PnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy4S4RKSzVyPUCuPEDDuSByLkGg{txO MmWyNlU5ODFyMEe=
S3 M3vMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETSSoxKSzVyPUWzMlUhyrFiMT61JO69VQ>? MkLvNlU5ODFyMEe=
AGS Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T1VGlEPTB;MUCuOkDPxE1? M2qz[lI2Pzh7MEW3
MKN-45 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPUTWM2OD1zND6wJO69VQ>? M{GyO|I2Pzh7MEW3
TMK-1 Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PZVWlEPTB;MkKuOkDPxE1? NVvHe|U5OjV5OEmwOVc>
SCM-1 NFKzbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LtOWlEPTB;MUeuOUDPxE1? MXeyOVc5QTB3Nx?=
HCT-15 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHIcGIyUUN3ME24MlY1KM7:TR?= M13neVI2PzZzNEe5
DiFi NYLLPHV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfDNVBKSzVyPUGwMlk2KM7:TR?= NWHnZpZ4OjV5NkG0O|k>
DLD-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjneodKSzVyPUiuOlUh|ryP M1P1VFI2PzZzNEe5
COLO-320DM M3;FTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DIRmlEPTB;NT6zPEDPxE1? NV:4WHNEOjV5NkG0O|k>
SNU-175 Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYK4RllLUUN3ME2xMlUyKM7:TR?= NHnkeFczPTd4MUS3PS=>
HT-29 M{jrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIToTXFKSzVyPUWuNlIh|ryP M1z0ZlI2PzZzNEe5
SW620 NFvTbYdHfW6ldHnvckBCe3OjeR?= NVyxcWVoOTEkgJpCuYcwdWx? MUCyOQKBkWh? M3zQc4lv[3KnYYPld{BNSzNvSVmgZYNkfW23bHH0bY9vKGGwZDDk[YNz\WG|ZYOgVFYzKGW6cILld5Nqd25? MYmyOVc1QTR{MB?=
SW480 NVSyWYJ2TnWwY4Tpc44hSXO|YYm= M37ZTlEx6oDLwsXnM41t M{PCSVI16oDLaB?= MV\pcoNz\WG|ZYOgUGM{NUmLIHHjZ5VufWyjdHnvckBidmRiZHXjdoVie2W|IGC2NkBmgHC{ZYPzbY9v MoD2NlU4PDl2MkC=
SW620 MkfCSpVv[3Srb36gRZN{[Xl? MYexNQKBkcL3Zz;tcC=> MVWyOQKBkWh? Ml7C[Y5p[W6lZYOgZ4VtdHWuYYKgZZV1d3CqYXfpZ{BndHW6 M2DseFI2PzR7NEKw
SW480 NGC4ZoxHfW6ldHnvckBCe3OjeR?= M1m1NFEx6oDLwsXnM41t MlKyNlTjiImq MVjlcohidmOnczDj[YxtfWyjcjDheZRweGijZ3njJIZtfXh? MnGxNlU4PDl2MkC=
A549 NGjtc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTVwODFCtUAxNjZizszN M4jrVFI2PjJ3MkSz
A549/CDDP MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\TTmxnUUN3ME2xPE43KMLzIEGuNkDPxE1? NF3TdmUzPTZ{NUK0Ny=>
Panc-1 NFrXbW1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXWyOU82OCEQvF2= NUPlUZpEOjRxNEigbC=> MnzxbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MoDRNlU1PDR7MUS=
MIAPaCa-2 MX3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWjWcXQ{OjVxNUCg{txO M{m3OFI1NzR6IHi= NHf5NlNqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? NYTO[IJROjV2NES5NVQ>
SW1990 NVzU[|BMS2WubDDWbYFjcWyrdImgRZN{[Xl? NUnkb25YOjVxNUCg{txO M{XselI1NzR6IHi= MkDZbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MkL0NlU1PDR7MUS=
HPDE NGS5Vm5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{\z[lI2NzVyIN88US=> NUHw[2syOjRxNEigbC=> NXvaSHp7cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD MX[yOVQ1PDlzNB?=
Panc-1 MljuRZBweHSxc3nzJGF{e2G7 MUKyOgKBkcL3TR?= MUWyOEBp M37LV4lv\HWlZYOgZZBweHSxc3nzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? MVOyOVQ1PDlzNB?=
MIAPaCa-2 Mn7vRZBweHSxc3nzJGF{e2G7 NVHYfWFsOjYkgJpCuW0> NHX2d4MzPCCq Mn7vbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? Mmj5NlU1PDR7MUS=
Panc-1 NH71cFFHfW6ldHnvckBCe3OjeR?= Ml\BNlXjiIoEtV2= MmniNlQwPDhiaB?= M4m5[Ylv\HWlZYOgZ4xm[X[jZ3Wgc4YhWEGUUDygZ4F{eGG|ZT25MEBk[XOyYYPlMVgh[W6mIHPhd5Bie2VvM9Mg Ml:wNlU1PDR7MUS=
MIAPaCa-2 M4XVeWZ2dmO2aX;uJGF{e2G7 NYr1WmFSOjYkgJpCuW0> MXiyOE81QCCq NYe3RY8{cW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG|ZT2zxsA> NGCxSXozPTR2NEmxOC=>
SW480 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XVbVczKGkEoB?= NXfNd291UUN3ME2xNE44yrF{LkK2JOK2\y:vTB?= NFvucpIzPTN4ME[zNS=>
HCT116  MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVi4fGhDPzJiaNMg M3nCZWlEPTB;Nj6yN:KyOC55NTFCuYcwdUx? MUiyOVM3ODZ|MR?=
COC1 M{\YRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDRTWM2OD12Nj6yNOKhyrIEoEOuNVQh|ryP Ml3nNlU{ODd2NEi=
SGC7901 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\sUoVtUUN3ME2yNU44O8LiwsJCpFMvODhizszN M13aW|I2OzB5NES4
A549 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\oemlEPTB;NUGuNFjDqMLzwrCxNE46PiEQvF2= NVnBfYxROjV|MEe0OFg>
HepG2 NUXOUGNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHq[pI6UUN3ME2xOE4zPMLiwsJCpFEvQDJizszN NG\aNGMzPTNyN{S0PC=>
MCF-7 NIfIU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{WyWmlEPTB;MUSuNlTDqMLzwrCxMlgzKM7:TR?= MkPiNlU{ODd2NEi=
HCT-116 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\5XmhKSzVyPU[uNlTDqMLzwrCyMlk4KM7:TR?= NEfPSnMzPTNyN{S0PC=>
HT-29 M1;Femdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;NTWM2OD53MDFOwG0> Mm\uNlU{ODd2NEi=
HEK293 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2SwZWlEPTB;OD64NuKhyrIEoEWuOVkh|ryP MXSyOVMxPzR2OB?=
HUVEC MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfLbpV1UUN3ME2xNU4{OMLiwsJCpFEvODJizszN NGrEdYEzPTNyN{S0PC=>
SW480 M1HyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;uSFHDqM7:TR?= MoHCNE04OiCq MXXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MlvCNlQ6QTd2NUG=
HT-29 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXyd2lNOcLizszN M1;0OVAuPzJiaB?= MWDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NEjQOVMzPDl7N{S1NS=>
HCT116 NEntdVJHfW6ldHnvckBCe3OjeR?= NHnJfo8zNzViwsXN NX\4d|VNOjRxNEigbC=> M3vib5N2eHC{ZYPz[ZMhe3W{dnn2bY4hdVKQQTDlfJBz\XO|aX;u NUDwZppqOjR5NkG0NVE>
SW480  M1X2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[0PEBpyqB? NYnDZZZ3UUN3ME2yNE45KHWpL33M MoPRNlQ4OjB4N{W=
SW620 NGSxNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7uVZgyOC15MDDt[{9N MX[yOE81QC95MjDo M3PMVYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MWmyOFY1PjNyNR?=
Caco2  M37Q[WZ2dmO2aX;uJGF{e2G7 M3i2cVMxyqEQvF2= MXqyOEBp MlLDSG1UVw>? NVnrb4lEcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBJVy1zLDDBT3IySyxiYX7kJG5SVzF? MWqyOFU2PjRzNR?=
Caco2  MnLCSpVv[3Srb36gRZN{[Xl? NX\sdoZ2Oy9zMD:zNEDPxE1? M4P3blE3KGh? MUfEUXNQ NFroUVBqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCDS2KxR|EtKE6TT{GsJGhQNTFuIF3SVFItyqCjbnTNVnA{yqCmb4PlMYRmeGWwZHXueIx6 NXmxfGhTOjR3NU[0NVU>
Caco2 MoHCSpVv[3Srb36gRZN{[Xl? Mmm0N|AwOTBywrFOwG0> Mln4NVbDqGh? MofCSG1UVw>? NEPNRmNi[3SrdnH0[ZMhVnKoMh?= Mor1NlQ2PTZ2MUW=

... Click to View More Cell Line Experimental Data

In vivo A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:[4]
+ Expand
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Formulation: Water solution
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMF Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% glucose (with warming)
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage powder
in solvent
Synonyms L-OHP

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03607643 Not yet recruiting Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme Leaf Vertical Inc. January 15 2019 Phase 1|Phase 2
NCT03516708 Not yet recruiting Rectal Cancer Washington University School of Medicine|Incyte Corporation January 31 2019 Phase 1|Phase 2
NCT03366155 Not yet recruiting Colorectal Cancer|Liver Metastases|Colorectal Adenocarcinoma|Colorectal Cancer With Hepatic Metastases|Colorectal Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 1 2019 Phase 2
NCT03698461 Not yet recruiting Colorectal Neoplasms|Neoplasm Metastasis|Colonic Neoplasms|Rectal Neoplasms Asan Medical Center|Hoffmann-La Roche December 2018 Phase 2
NCT03203525 Not yet recruiting Liver Cancer M.D. Anderson Cancer Center|NovoCure Ltd. December 2018 Phase 1
NCT03721653 Not yet recruiting Metastatic Colorectal Cancer Gruppo Oncologico del Nord-Ovest|Roche Pharma AG November 15 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID